<code id='ECECD7EECD'></code><style id='ECECD7EECD'></style>
    • <acronym id='ECECD7EECD'></acronym>
      <center id='ECECD7EECD'><center id='ECECD7EECD'><tfoot id='ECECD7EECD'></tfoot></center><abbr id='ECECD7EECD'><dir id='ECECD7EECD'><tfoot id='ECECD7EECD'></tfoot><noframes id='ECECD7EECD'>

    • <optgroup id='ECECD7EECD'><strike id='ECECD7EECD'><sup id='ECECD7EECD'></sup></strike><code id='ECECD7EECD'></code></optgroup>
        1. <b id='ECECD7EECD'><label id='ECECD7EECD'><select id='ECECD7EECD'><dt id='ECECD7EECD'><span id='ECECD7EECD'></span></dt></select></label></b><u id='ECECD7EECD'></u>
          <i id='ECECD7EECD'><strike id='ECECD7EECD'><tt id='ECECD7EECD'><pre id='ECECD7EECD'></pre></tt></strike></i>

          
          WSS
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive